AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, M. M.
Right arrow Articles by Wrensch, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, M. M.
Right arrow Articles by Wrensch, M. R.
Related Collections
Right arrow Health Care Facilities/Services
Right arrow Other Race/Ethnicity
Right arrow Men's Health
Right arrow Cancer
October 2002, Vol 92, No. 10 | American Journal of Public Health 1606-1609
© 2002 American Public Health Association


RESEARCH AND PRACTICE

Complementary and Alternative Medicine Use Among Men With Prostate Cancer in 4 Ethnic Populations

Marion M. Lee, PhD, MPH, Jeffrey S. Chang, MD, MPH, Bradly Jacobs, MD, MPH and Margaret R. Wrensch, PhD

Marion M. Lee, Jeffrey S. Chang, and Margaret R. Wrensch are with the Department of Epidemiology and Biostatistics, University of California, San Francisco. Bradly Jacobs is with the Osher Center for Integrative Medicine, Department of Medicine, University of California, San Francisco.

Correspondence: Requests for reprints should be sent to Marion M. Lee, PhD, MPH, Department of Epidemiology and Biostatistics, University of California, Box 0560, San Francisco, CA 94143-0560 (e-mail: mlee{at}epi.ucsf.edu).


    INTRODUCTION
 TOP
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION AND CONCLUSIONS
 References
 
In the United States, prevalence rates of complementary and alternative medicine (CAM) use in the general population have increased in recent years (e.g., from 33.8% in 1990 to 42.1% in 1997).1 Among cancer patients, rates of CAM use are usually higher than among the general population.2–5 Few studies have specifically targeted prostate cancer patients,6–9 and, to our knowledge, no study has examined ethnic differences in CAM use among prostate cancer patients. In the present research, we examined prevalence rates and correlates of CAM use among men from 4 ethnic groups (White, Black, Hispanic, and Asian, including Chinese, Filipino, and Japanese) residing in the San Francisco Bay Area.


    METHODS
 TOP
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION AND CONCLUSIONS
 References
 
Study participants were male San Francisco Bay Area residents between the ages of 40 and 89 years who had been diagnosed with (histologically confirmed) primary invasive localized, regional, or remote prostate cancer. Men diagnosed in 1998 were identified by ethnicity through the regional tumor registry operated by the Northern California Cancer Center. We conducted telephone interviews from September 1999 through April 2001 with a standardized questionnaire in the participant’s language of choice (English, Spanish, Mandarin, or Cantonese).

The questionnaire collected information on demographic characteristics; acculturation (country of birth and language spoken at home); family history of prostate cancer; participation in religious, recreational, professional, or other social groups; other illnesses; smoking status; alcohol consumption; exercise; types of conventional therapy undergone for prostate cancer; and types of CAM used for prostate cancer (Table 1Go). Details on the types of CAM that were included were described in an earlier article.2


View this table:
[in this window]
[in a new window]
 
TABLE 1 —Rates of Use of Various Complementary/Alternative Medicine Therapies (CAM): Men Diagnosed With Prostate Cancer in 1998 in the San Francisco Bay Area
 
The primary outcome of interest was prevalence of CAM use related to prostate cancer diagnosis. Chi-square tests were used in comparisons of demographic characteristics of CAM users and nonusers.

Logistic regression analyses were conducted to determine associations between covarying variables and CAM use (Table 2Go). Variables that were significant at the P < .05 level and variables that had odds ratios of 1.5 or more or of 0.5 or less in univariate analyses were entered into a multivariate logistic regression model to determine their relative importance in association with CAM use.


View this table:
[in this window]
[in a new window]
 
TABLE 2 —Factors Associated With Complementary/Alternative Medicine (CAM) Use: Men Diagnosed With Prostate Cancer in 1998 in the San Francisco Bay Area
 
Statistical analyses were performed with SAS, version 8.10 (SAS Institute Inc, Cary, NC). All P values were 2-tailed.


    RESULTS
 TOP
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION AND CONCLUSIONS
 References
 
Of 690 men reachable by telephone, 543 (79%) completed a 30-minute telephone interview. Overall, 30% of our participants used at least 1 type of CAM. CAM users were slightly younger than nonusers (65.5 vs 66.9 years; P = .07), and they were more likely to be college graduates (65.0% vs 53.8%; P = .02). CAM users and nonusers were similar in terms of income level, country of birth, and marital status.

Table 1Go shows percentages of men using specific types of CAM by ethnicity. As can be seen, prevalence rates of CAM use and types of CAM used varied greatly according to ethnicity. Table 2Go presents data on factors associated with CAM use. It is evident that factors influencing CAM use varied by ethnicity as well.


    DISCUSSION AND CONCLUSIONS
 TOP
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION AND CONCLUSIONS
 References
 
Among our respondents, the overall prevalence of CAM use related to prostate cancer was 30%, which is within the range of rates previously reported among prostate cancer patients (27.4%–43%).6–9 Consistent with previous investigations,2,7,10–15 our study found that CAM use was associated with younger age, higher educational level, regular exercise, influence on the part of friends and relatives with prostate cancer, and participation in social or religious groups.

To our knowledge, this is the first study of CAM therapy use among prostate cancer patients to involve significant percentages of non-English-speaking (15%) and Asian (20%) participants. When we examined members of each ethnic group separately, we found differences in correlates of CAM use. Among members of different ethnic groups, it is likely that use is influenced by individual cultural norms and experiences.16

This study involved several limitations. First, the study population, from the ethnically diverse San Francisco Bay Area, may not be comparable to samples from other parts of the country with different ethnic compositions. Second, we included only 3 Asian ethnic groups, and thus the results may not be representative of all Asian ethnic groups in the United States. Finally, because the study was cross sectional, the associations found may not reflect effects of 1 factor on another.

It is important for physicians to ascertain whether their patients are using CAM, in that many CAM therapies may affect the body’s physiological functioning and be associated with drug interactions.17–19 In addition, previous studies have shown that CAM use may be related to emotional distress.13,20 Initiating discussions regarding CAM use and reasons for use may be a good way for physicians to assess patients’ emotional status and to provide emotional support.

In light of the ethnic differences in correlates of CAM use revealed in our study, future research should examine patterns of CAM use and reasons associated with use among different racial/ethnic groups. Such ethnicity-specific data will be important in helping physicians understand motivations behind CAM use and in facilitating effective discussions with patients.


    Acknowledgments
 
This research was supported by the California Cancer Research Program (grant 99-00535V-10239).

We thank Scarlett Lin, Jade Lin, Vance Ingalls, Veronica Gov, Sue Zhou, Guillermo Torano, Jeffrey Chu, Maria Diaz-Mendez, Michael Hsu, Garrett Tichauer, Casey Hart, Rita Leung, and Christine Choy for their assistance in various stages of the study.

Human Participant Protection
Because the data for this study were gathered through telephone interviews, written consent was not obtained. However, we did obtain verbal consent via telephone from each participant before we began the interview process. This process was approved by the Committee on Human Subject Research at the University of California, San Francisco.


    Footnotes
 
M. M. Lee, B. Jacobs, and M. R. Wrensch contributed to the study concept and design. All of the authors contributed to the acquisition, analysis, and interpretation of data and to the drafting of the brief.

Peer Reviewed

Accepted for publication June 4, 2002.


    References
 TOP
 INTRODUCTION
 METHODS
 RESULTS
 DISCUSSION AND CONCLUSIONS
 References
 
1. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280:1569–1575.[Abstract/Free Full Text]

2. Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D. Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst. 2000;92:42–47.[Abstract/Free Full Text]

3. Sparber A, Bauer L, Curt G, et al. Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum. 2000;27:623–630.[Medline]

4. Von Gruenigen VE, White LJ, Kirven MS, Showalter AL, Hopkins MP, Jenison EL. A comparison of complementary and alternative medicine use by gynecology and gynecologic oncology patients. Int J Gynecol Cancer. 2001;11:205–209.[Medline]

5. Adler SR, Fosket JR. Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract. 1999;48:453–458.[Medline]

6. Nam RK, Fleshner N, Rakovitch E, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol. 1999;161:1521–1524.[Medline]

7. Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer. 2000;88:615–619.[Medline]

8. Lippert MC, McClain R, Boyd JC, Theodorescu D. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer. 1999;86:2642–2648.[Medline]

9. Lubeck DP, Litwin MS, Flanders SC, Henning JM, Carroll PR. Use of complementary and alternative medicine (CAM) treatments among a cohort of newly diagnosed prostate cancer patients: data from CapSUREO [abstract]. Abstract Book Assoc Health Serv Res. 1999;16:37.

10. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505–2514.[Abstract/Free Full Text]

11. Gotay CC, Hara W, Issell BF, Maskarinec G. Use of complementary and alternative medicine in Hawaii cancer patients. Hawaii Med J. 1999;58:94–98.[Medline]

12. Crocetti E, Crotti N, Feltrin A, Ponton P, Geddes M, Buiatti E. The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer. 1998;34:324–328.

13. Paltiel O, Avitzour M, Peretz T, et al. Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol. 2001;19:2439–2448.[Abstract/Free Full Text]

14. Leung JM, Dzankic S, Manku K, Yuan S. The prevalence and predictors of the use of alternative medicine in presurgical patients in five California hospitals. Anesth Analg. 2001;93:1062–1068.[Abstract/Free Full Text]

15. Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279:1548–1553.[Abstract/Free Full Text]

16. Maskarinec G, Shumay DM, Kakai H, Gotay CC. Ethnic differences in complementary and alternative medicine use among cancer patients. J Altern Complementary Med. 2000;6:531–538.[Medline]

17. Smolinske SC. Dietary supplement-drug interactions. J Am Med Womens Assoc. 1999;54:191–192, 195.

18. Ang-Lee MK, Moss J, Yuan CS. Herbal medicine and perioperative care. JAMA. 2001;286:208–216.[Abstract/Free Full Text]

19. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998;339:785–791.[Abstract/Free Full Text]

20. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999;340:1733–1739.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
JCOHome page
C. M. Velicer and C. M. Ulrich
Vitamin and Mineral Supplement Use Among US Adults After Cancer Diagnosis: A Systematic Review
J. Clin. Oncol., February 1, 2008; 26(4): 665 - 673.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
B. R. Cassileth, G. E. Deng, J. E. Gomez, P. A. S. Johnstone, N. Kumar, and A. J. Vickers
Complementary Therapies and Integrative Oncology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 340S - 354S.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
B. I Ortiz, K. M Shields, K. A Clauson, and P. G Clay
Complementary and Alternative Medicine Use Among Hispanics in the United States
Ann. Pharmacother., June 1, 2007; 41(6): 994 - 1004.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Tascilar, F. A. de Jong, J. Verweij, and R. H. J. Mathijssen
Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence
Oncologist, July 1, 2006; 11(7): 732 - 741.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. K. Dy, L. Bekele, L. J. Hanson, A. Furth, S. Mandrekar, J. A. Sloan, and A. A. Adjei
Complementary and Alternative Medicine Use by Patients Enrolled Onto Phase I Clinical Trials
J. Clin. Oncol., December 1, 2004; 22(23): 4810 - 4815.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
R. Struthers and V. S. Eschiti
The Experience of Indigenous Traditional Healing and Cancer
Integr Cancer Ther, March 1, 2004; 3(1): 13 - 23.
[Abstract] [PDF]


Home page
The OncologistHome page
B. R. Cassileth and G. Deng
Complementary and Alternative Therapies for Cancer
Oncologist, February 1, 2004; 9(1): 80 - 89.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, M. M.
Right arrow Articles by Wrensch, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, M. M.
Right arrow Articles by Wrensch, M. R.
Related Collections
Right arrow Health Care Facilities/Services
Right arrow Other Race/Ethnicity
Right arrow Men's Health
Right arrow Cancer


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Public Health Association